Replies to post #190695 on Biotech Values

[pollyvonwog]

~260,000 patients or 4% of the estimated 6.6 million infected population (U.S. ~4.0 million and Big-5 ~2.6 million) have been treated with a sofosbuvir-based regimen since December 2013.

Plenty of market left according to GILD.